5-hydroxytryptamine1A receptor density in the hippocampus of patients with temporal lobe epilepsy is associated with disease duration

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFONSECA, N. C.
dc.contributor.authorJOAQUIM, H. P. G.
dc.contributor.authorTALIB, L. L.
dc.contributor.authorVINCENTIIS, S.
dc.contributor.authorGATTAZ, W. F.
dc.contributor.authorVALENTE, K. D.
dc.date.accessioned2017-06-09T15:37:19Z
dc.date.available2017-06-09T15:37:19Z
dc.date.issued2017
dc.description.abstractBackground and purpose: : To date, no study has evaluated the association between serotonin receptor density and clinical variables in patients with temporal lobe epilepsy caused by hippocampal sclerosis (TLE-HS) using hippocampal tissue. We evaluated 5-hydroxytryptamine1A receptor (5-HT1AR) density in hippocampal tissue from patients with TLE-HS. Methods: We analyzed the hippocampal tissue of 34 patients with pharmacoresistant unilateral TLE-HS. 5-HT1AR density was measured using semiquantitative western blotting. Results: There was an association between higher density of 5-HT1AR and longer duration of epilepsy (Spearman correlation: P = 0.040; generalized linear model: P = 0.026). Conclusions: This study demonstrated that hippocampal 5-HT1AR density is associated with epilepsy duration in patients with TLE-HS. The authors postulate that this may represent a potential regulatory enhancement of endogenous serotonergic neurotransmission in response to prolonged and enduring epileptiform activity in the hippocampal tissue of patients with pharmacoresistant TLE-HS.
dc.description.indexMEDLINE
dc.description.sponsorshipNational Council of Technological and Scientific Development (CNPq)
dc.description.sponsorshipAgency of the Sao Paulo Research Foundation (FAPESP)
dc.identifier.citationEUROPEAN JOURNAL OF NEUROLOGY, v.24, n.4, p.602-608, 2017
dc.identifier.doi10.1111/ene.13252
dc.identifier.eissn1468-1331
dc.identifier.issn1351-5101
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/20159
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofEuropean Journal of Neurology
dc.rightsrestrictedAccess
dc.rights.holderCopyright WILEY
dc.subjectepilepsy surgery
dc.subjecthippocampal sclerosis
dc.subjecthippocampus
dc.subjectrefractory
dc.subjectserotonin
dc.subjectwestern blotting
dc.subject.otherspike-wave discharges
dc.subject.othergenetic rat model
dc.subject.other5-ht1a receptors
dc.subject.otherprone rats
dc.subject.otheranticonvulsant action
dc.subject.otherabsence epilepsy
dc.subject.otherseizure activity
dc.subject.otherserotonin
dc.subject.otherbinding
dc.subject.otherstimulation
dc.subject.wosClinical Neurology
dc.subject.wosNeurosciences
dc.title5-hydroxytryptamine1A receptor density in the hippocampus of patients with temporal lobe epilepsy is associated with disease duration
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus8
hcfmusp.contributor.author-fmusphcNATASCHA CARDOSO DA FONSECA
hcfmusp.contributor.author-fmusphcHELENA PASSARELLI GIROUD JOAQUIM
hcfmusp.contributor.author-fmusphcLEDA LEME TALIB
hcfmusp.contributor.author-fmusphcSILVIA DE VINCENTIIS
hcfmusp.contributor.author-fmusphcWAGNER FARID GATTAZ
hcfmusp.contributor.author-fmusphcKETTE DUALIBI RAMOS VALENTE
hcfmusp.description.beginpage602
hcfmusp.description.endpage608
hcfmusp.description.issue4
hcfmusp.description.volume24
hcfmusp.origemWOS
hcfmusp.origem.pubmed28188677
hcfmusp.origem.scopus2-s2.0-85012900977
hcfmusp.origem.wosWOS:000397984800014
hcfmusp.publisher.cityHOBOKEN
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAssem-Hilger E, 2010, EPILEPSY BEHAV, V19, P467, DOI 10.1016/j.yebeh.2010.07.030
hcfmusp.relation.referenceBlumcke I, 2012, BRAIN PATHOL, V22, P402, DOI 10.1111/j.1750-3639.2012.00583.x
hcfmusp.relation.referenceBogaert PV, 2001, EPILEPSY RES, V47, P127
hcfmusp.relation.referenceBrowning RA, 1997, EUR J PHARMACOL, V336, P1, DOI 10.1016/S0014-2999(97)01215-6
hcfmusp.relation.referenceChugani DC, 1998, ANN NEUROL, V44, P858, DOI 10.1002/ana.410440603
hcfmusp.relation.referenceClinckers R, 2004, J NEUROCHEM, V89, P834, DOI 10.1111/j.1471-4159.2004.02355.x
hcfmusp.relation.referenceClough R, 1996, NEUROREPORT, V8, P341, DOI 10.1097/00001756-199612200-00067
hcfmusp.relation.referenceda Fonseca NC, 2015, EPILEPSY RES, V111, P18, DOI 10.1016/j.eplepsyres.2014.12.013
hcfmusp.relation.referenceDAILEY JW, 1992, LIFE SCI, V50, P319, DOI 10.1016/0024-3205(92)90340-U
hcfmusp.relation.referenceDAILEY JW, 1989, EPILEPSY RES, V3, P3, DOI 10.1016/0920-1211(89)90063-6
hcfmusp.relation.referenceDidelot A, 2008, BRAIN, V131, P2751, DOI 10.1093/brain/awn220
hcfmusp.relation.referenceFilakovszky J, 1999, NEUROSCI LETT, V261, P89, DOI 10.1016/S0304-3940(99)00015-4
hcfmusp.relation.referenceGariboldi M, 1996, BRIT J PHARMACOL, V119, P813
hcfmusp.relation.referenceGerber K, 1998, BRAIN RES, V807, P243, DOI 10.1016/S0006-8993(98)00801-4
hcfmusp.relation.referenceGiovacchini G, 2005, J NUCL MED, V46, P1128
hcfmusp.relation.referenceGraebenitz S, 2011, BRAIN, V134, P2929, DOI 10.1093/brain/awr202
hcfmusp.relation.referenceJakus R, 2003, EXP NEUROL, V184, P964, DOI 10.1016/S0014-4886(03)00352-2
hcfmusp.relation.referenceJiang XL, 2009, NEUROPSYCHOPHARMACOL, V34, P410, DOI 10.1038/npp.2008.71
hcfmusp.relation.referenceJobe PC, 2000, CNS DRUG REV, V6, P241
hcfmusp.relation.referenceKim DS, 2007, BRAIN RES, V1154, P181, DOI 10.1016/j.brainres.2007.03.084
hcfmusp.relation.referenceKwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
hcfmusp.relation.referenceLiew CJ, 2009, EPILEPSIA, V50, P234, DOI 10.1111/j.1528-1167.2008.01789.x
hcfmusp.relation.referenceLopez-Meraz ML, 2005, NEUROPHARMACOLOGY, V49, P367, DOI 10.1016/j.neuropharm.2005.03.020
hcfmusp.relation.referenceLOWRY OH, 1951, J BIOL CHEM, V193, P265
hcfmusp.relation.referenceLu KT, 1998, NEUROSCIENCE, V86, P729, DOI 10.1016/S0306-4522(98)00106-7
hcfmusp.relation.referenceMahmood Tahrin, 2012, N Am J Med Sci, V4, P429, DOI 10.4103/1947-2714.100998
hcfmusp.relation.referenceMarinova Z, 2015, NEUROPATH APPL NEURO, V41, P520, DOI 10.1111/nan.12167
hcfmusp.relation.referenceMartinez A, 2013, NEUROLOGY, V80, P1465, DOI 10.1212/WNL.0b013e31828cf809
hcfmusp.relation.referencePalomero-Gallagher N, 2012, EPILEPSIA, V53, P1987, DOI 10.1111/j.1528-1167.2012.03634.x
hcfmusp.relation.referencePericic D, 2005, EUR J PHARMACOL, V527, P105, DOI 10.1016/j.ejphar.2005.10.021
hcfmusp.relation.referenceRocha L, 2007, PROG NEURO-PSYCHOPH, V31, P1208, DOI 10.1016/j.pnpbp.2007.04.014
hcfmusp.relation.referenceSalgado-Commissariat D, 1997, NEUROPHARMACOLOGY, V36, P1705, DOI 10.1016/S0028-3908(97)00134-2
hcfmusp.relation.referenceSmolders I, 2008, NEUROPHARMACOLOGY, V54, P1017, DOI 10.1016/j.neuropharm.2008.02.006
hcfmusp.relation.referenceSperanza L, 2013, NEUROPHARMACOLOGY, V67, P155, DOI 10.1016/j.neuropharm.2012.10.026
hcfmusp.relation.referenceStatnick MA, 1996, NEUROPHARMACOLOGY, V35, P111, DOI 10.1016/0028-3908(95)00141-7
hcfmusp.relation.referenceTrottier S, 1996, EPILEPSY RES, V25, P79, DOI 10.1016/0920-1211(96)00033-2
hcfmusp.relation.referenceVermoesen K, 2012, EPILEPSIA, V53, P870, DOI 10.1111/j.1528-1167.2012.03436.x
hcfmusp.relation.referenceWada Y, 1997, BRAIN RES, V747, P338, DOI 10.1016/S0006-8993(96)01322-4
hcfmusp.relation.referenceWADA Y, 1993, NEUROSCI LETT, V159, P179, DOI 10.1016/0304-3940(93)90828-9
hcfmusp.relation.referenceWang L, 2015, MOL NEUROBIOL, V51, P1292, DOI 10.1007/s12035-014-8806-6
hcfmusp.relation.referenceWatanabe K, 2000, EUR J PHARMACOL, V398, P239, DOI 10.1016/S0014-2999(00)00258-2
hcfmusp.relation.referenceYAN QS, 1994, EUR J PHARMACOL, V252, P105, DOI 10.1016/0014-2999(94)90581-9
hcfmusp.relation.referenceYang ZY, 2012, EUR J PHARMACOL, V685, P52, DOI 10.1016/j.ejphar.2012.04.011
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication7809bafe-ba48-4024-a0c9-26d4b6aa5ada
relation.isAuthorOfPublicationb878d19c-9026-4210-b53b-6c4eddb6ee7f
relation.isAuthorOfPublication65a65251-2a2e-454e-991f-07d85966f440
relation.isAuthorOfPublication9186941b-c582-4aa1-a9ad-ede4cc1450e4
relation.isAuthorOfPublication125dcc9f-a05a-42fd-ab1d-b6db35d2616b
relation.isAuthorOfPublication3bb20e3c-b17a-4598-a9d8-4037c72e98a3
relation.isAuthorOfPublication.latestForDiscovery7809bafe-ba48-4024-a0c9-26d4b6aa5ada
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_FONSECA_5hydroxytryptamine1A_receptor_density_in_the_hippocampus_of_patients_2017.PDF
Tamanho:
303.14 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21
Artigos e Materiais de Revistas Científicas - LIM/27